Current Promotions

No active promotions at the moment. Check back later for special offers!

No video available

Get in Touch

Call Now Visit Website

About

Actinogen Medical (ASX:ACW) is an ASX-listed biotechnology company developing a novel therapy for neurological and neuropsychiatric diseases associated with dysregulated brain cortisol.

There is a strong association between persistent stress and the production of excess cortisol that leads to changes in the brain affecting memory, cognitive function, behaviour and neuropsychological symptoms.

Actinogen's lead compound, Xanamem, has been specifically designed to reduce production of intracellular cortisol - the stress hormone - through the inhibition of the 11β-HSD1 enzyme in the brain. The 11β-HSD1 enzyme is highly concentrated in the areas of the brain associated with cognitive impairment in early Alzheimer's Disease (AD) and Depression, and other neurological and psychiatric diseases. Because of its ability to reach these areas of the brain and inhibit this enzyme, Xanamem is very different from other treatments for cognitive impairment.

Actinogen has studied 11β-HSD1 inhibition by Xanamem in more than 300 volunteers and patients, so far finding a statistically significant improvement in working memory and attention, compared with placebo, in healthy, older volunteers in two consecutive trials and clinically significant improvements in patients with biomarker-positive mild AD. Previously, high levels of target engagement in the brain with doses as low as 5 mg daily have been demonstrated in a human PET imaging study.

The Company is rapidly moving forward into its upcoming double-blind, randomized, placebo-controlled Phase 2 trials in cognitive impairment in Alzheimer's Disease and Depression to further confirm and characterize Xanamem's therapeutic potential. The XanaMIA Phase 2b AD trial comprises 330 patients with mild Alzheimer's Disease and the XanaCIDD Phase 2a trial will total 160 patients with depression.

Keywords

biotechnology, clinical development, pharmaceuticals, clinical research

Amenities

No amenities listed yet

Upcoming Events

No upcoming events scheduled

Frequently Asked Questions

No FAQs available for this business.

Reviews

No reviews yet. Be the first to review!

Social Links

Photo Gallery

No photos available

Contact Information

Business Info

16
2014
$4.5M

Business Hours

Business hours not available

Own This Business?

Unclaimed

Take control of your business page to update information, respond to reviews, and more.

Claim This Business